



Field evaluation of a dual rapid Human Immunodeficiency Virus and treponemal syphilis rapid test in community-based clinics in Los Angeles and New York ☆☆☆☆

Chrysovalantis Stafylis ^{a,*}, Claire C Bristow ^b, Lauren J Natoli ^c, Katheryn R Salow ^c, Emma Davidson ^c, Yancy Granados ^c, Mark McGrath ^c, Jeffrey D Klausner ^a

^a David Geffen School of Medicine at UCLA, 10920 Wilshire Blvd, Los Angeles, CA, 90024, USA

^b Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr 0507, La Jolla, CA 92093, USA

^c AIDS Healthcare Foundation, 1811 N Western Ave, Los Angeles, CA, 90027, USA

ARTICLE INFO

Article history:

Received 31 May 2018

Received in revised form 9 September 2018

Accepted 3 October 2018

Available online 11 October 2018

Keywords:

Diagnosis

Treponema pallidum

HIV

Rapid test

Dual test

ABSTRACT

Introduction: Dual human immunodeficiency virus/syphilis rapid diagnostic devices can play an important role in prevention efforts. The field performance of the INSTI Multiplex HIV-1/HIV-2/Syphilis Antibody Test (Multiplex) was evaluated.

Methods: Fingerstick whole blood was tested using the rapid test. A fourth-generation HIV laboratory assay and treponemal-specific laboratory assays were used as reference. Rapid plasma reagin (RPR) was used to stratify treponemal results. Sensitivity and specificity were calculated.

Results: Overall, 274 patients participated. Sensitivity of the Multiplex for detection of HIV was 98.8% (95% CI, 93.4–100%), and specificity was 100% (95% CI, 98.1–100%). Sensitivity for detection of syphilis antibodies was 56.8% (95% CI, 44.7–68.2%), and specificity was 98.5% (95% CI, 95.7–99.7%). Sensitivity for treponemal antibodies improved with increasing RPR and was 100% (95% CI, 78.2–100%) among samples with RPR titers $\geq 1:8$.

Conclusions: The Multiplex showed excellent performance for detection of HIV antibodies and increasing sensitivity for detection of treponemal antibody with increasing RPR titer.

© 2018 Elsevier Inc. All rights reserved.

1. Introduction

Despite a decrease in the number of new cases of human immunodeficiency virus (HIV) infection (Centers for Disease Control and Prevention, 2016, 2018), the rate of new syphilis cases in the United States is increasing (Centers for Disease Control and Prevention, 2016, 2018). Men who have sex with men account for the majority of new HIV and syphilis cases, and the rate of HIV/syphilis co-infection is also very high (Centers for Disease Control and Prevention, 2016, 2018).

Syphilis infection can facilitate transmission and acquisition of HIV (Zetola and Klausner, 2007). Novel diagnostic strategies for timely identification and treatment are needed to reduce the burden of those infections and reduce transmission.

Dual rapid assays are point-of-care tests that simultaneously detect antibodies for HIV and *Treponema pallidum* (TP), the organism that causes syphilis. They offer a convenient way to screen for both infections using 1 specimen and 1 test. Dual testing requires a single finger prick, which reduces patient discomfort, and may have the potential to reduce costs (Bristow et al., 2016). This could have significant applications in resource-limited areas, populations with high prevalence of both infections, antenatal screening, and population-targeted screening. Despite obvious advantages of these dual tests, to date, there is no FDA-approved dual device test for use in the United States.

The INSTI Multiplex HIV-1/HIV-2/Syphilis Antibody Test (BioLytical, Richmond, BC, Canada) is a new rapid point-of-care device for the detection of antibodies to HIV and TP, and it has shown high performance in laboratory evaluations (Herbst de Cortina et al., 2016). The goal of this study was to evaluate the field performance of the INSTI Multiplex in a community clinical setting using laboratory-based reference tests and

☆ Conflicts of interest statement: INSTI Multiplex tests were donated by the manufacturer, BioLytical, Richmond, BC, Canada.

☆☆ Funding: This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers T32AI007384 (to CCB) and K01AI136725 (to CCB); the UCLA Center for AIDS Research (P30AI028697 to J.D.K.); and National Institutes of Health UCLA Center for HIV Identification, Prevention and Treatment Services (P30MH058107 to J.D.K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

* Data statement: Data are available upon request from the corresponding author.

* Corresponding author. Tel.: +1 (626) 757 8602.

E-mail address: chrstafylis@outlook.com (C. Stafylis).

to compare it to the performance of the currently used standard of care rapid screening assays for HIV and syphilis.

2. Methodology

2.1. Study population and setting

Eligible participants were ≥18 years old who presented to 4 outpatient clinics of the AIDS Healthcare Foundation (AHF) in Los Angeles and in New York City between August 2016 and December 2017. The clinics provide health care to patients with HIV infection and offer free HIV and sexually transmitted diseases testing. Participants gave oral informed consent for participation. A \$25 gift card was given to all participants for their time.

2.2. Under evaluation assays

The INSTI Multiplex is a single use, rapid flow-through in vitro qualitative immunoassay for the detection of antibodies to HIV-1, HIV-2, and TP in human whole blood, fingerstick blood, serum, or plasma (bioLytical Laboratories Inc.). The test detects IgG antibodies to gp41 antigen (HIV-1), gp36 antigen (HIV-2), and p17 and p47 domains of TP. The test cartridge has 3 dots for result interpretation: 1 for the internal control, 1 for HIV, and another for TP antibodies. The kit result does not differentiate between HIV-1 and HIV-2 antibody detection. Test results can be read within 1 min of inoculation with the specimen.

Two rapid tests are currently used at AHF clinics for HIV and syphilis screening: the INSTI® HIV-1/HIV-2 Rapid Antibody Test (BioLytical, Richmond, BC, Canada) and the Syphilis Health Check (Diagnostics Direct, LLC, Stone Harbor, NJ, USA), respectively. The INSTI HIV test follows the same procedures as the INSTI Multiplex and contains the same HIV antibody targets. The Syphilis Health Check yields results in 10 min and detects TP-specific antibodies for p15, p17, and p44 domains of the TP (Trinity Biotect Plc.). Fig. 1 shows the technical characteristics from the test package inserts of all the rapid tests used in the study.

Testing with each rapid test (INSTI Multiplex, INSTI HIV, and Syphilis Health Check) requires 50 µL of blood, which is equal to 2 drops of blood.

Fingerstick whole blood was tested on each rapid test. Specimen collection and testing were performed by a trained counselor according to the manufacturer's instructions.

A venipuncture specimen was also collected from each participant, and serum was used to perform HIV and syphilis reference testing. Participant infection status for HIV was determined using a fourth-generation assay. The Los Angeles sites used the Abbott ARCHITECT HIV Ag/Ab Combo (Abbott, IL, USA), and the New York sites the fourth-generation ADVIA Centaur XP HIV-1/O/2 Antigen/Antibody (Siemens, USA). For syphilis, the infection status was determined using the TP particle agglutination (Serodia TPPA, Fujirebio Inc., PA) in Los Angeles sites and TP Enzyme Immunoassay (TPEIA; Bioplex 2200, Bio-Rad Industries, CA, USA) in New York. Rapid plasma reagin (RPR; Gold Standard Diagnostics, CA, USA) was performed on TP-positive specimens.

2.3. Data analysis

We extracted demographic information (gender, age) from patient medical records. Data from all sites were combined before analysis. A sample was considered positive for HIV if it tested positive in either fourth-generation HIV assay. Similarly, a sample was considered positive for TP antibodies if it tested positive in either TPPA or TPEIA.

The sensitivity and specificity of the 3 rapid devices for the detection of HIV and TP antibody detection were calculated; in addition, sensitivity for TP antibody detection was stratified by RPR titer (nonreactive, 1:1–1:2, 1:4, ≥1:8). Concordance between the experimental device and the reference laboratory tests was calculated using Cohen's kappa statistic. The exact binomial method was used to determine 95% confidence intervals (CI). Data analysis was conducted using the IBM SPSS version 22. The 2-proportion z-test was used to assess difference in sensitivity in syphilis detection between the 2 rapid tests for TP detection. A result was considered significant when the *P* value was less than 0.05.

2.4. Human subjects review approval

The study was approved by the UCLA Institutional Review Board with IRB# 16-000489.

Technical characteristics	INSTI® HIV-1/HIV-2 Rapid Antibody Test (bioLytical Laboratories Inc.)	INSTI® Multiplex HIV-1/HIV-2/Syphilis Antibody Test (bioLytical Laboratories Inc.)	Syphilis Health Check (Trinity Biotect Plc.)
Method	Qualitative immunoassay	Qualitative immunoassay	Qualitative immunochromatographic assay
Antigens	HIV-1 (M,O), HIV-2: IgG antibodies to gp41 antigen (HIV-1) gp36 antigen (HIV-2)	HIV-1 (M,O), HIV-2: IgG antibodies to gp41 antigen (HIV-1) gp36 antigen (HIV-2) Treponema pallidum: tp17 and tp47 proteins	Treponema pallidum: IgG and IgM antibodies for tp15, tp17, and tp44
Sample type	Serum, whole blood, plasma, fingerstick	Serum, whole blood, plasma, fingerstick	Serum, whole blood, plasma, fingerstick
Sample size	50ul	50ul	50ul
Result turnover	1 minute	1 minute	10 minutes
Reported accuracy (Sensitivity/Specificity)	For HIV: Venous Whole Blood: 99.9%/100% Plasma, Serum: 99.9%/100% Fingerstick: 99.8%/ 99.5%	For HIV: Venous Whole Blood 99.4%/99.7% Plasma: 99.5%/100% Fingerstick: 99.6%/99.3% Serum: 99%/ 100% Syphilis: 100%/100% (secondary syphilis; serum and whole blood)	Serum: 89.8%/92.3%

Fig. 1. Manufacturer technical characteristics of the rapid test under evaluation (INSTI Multiplex) and the standard-of-care rapid tests used by the clinics.

Table 1

Performance of the INSTI Multiplex HIV-1/HIV-2/Syphilis Antibody Test kit, the INSTI HIV-1/HIV-2 Antibody Test kit, and Syphilis Health Check.*a, **b

HIV antibody detection ^a					
	Positive (<i>n</i> = 82)	Negative (<i>n</i> = 192)	Sensitivity 95% CI	Specificity 95% CI	Cohen's kappa statistic
Multiplex HIV	81	192	98.8% (93.40–100%)	100% (98.1–100%)	0.99 (0.97–1)
INSTI HIV	81	192			
TP antibody detection ^b					
	Positive (<i>n</i> = 74)	Negative (<i>n</i> = 200)	Sensitivity 95% CI	Specificity 95% CI	Cohen's kappa statistic
Multiplex TP	42	197	56.8% (44.7–68.2%)	98.5% (95.7–99.7%)	0.63 (0.52–0.74)
Syphilis Health Check	54	194	73% (61.4–82.6%)	97% (93.6–98.9%)	0.75 (0.56–0.86)

^a Reference tests: Abbott ARCHITECT HIV Ag/Ab Combo; fourth-generation ADVIA Centaur XP HIV-1/O/2 Antigen/Antibody.^b Reference tests: Serodia TPPA, Fujirebio Inc., PA, USA; TPEIA Bioplex 2200, Bio-Rad Industries, CA, USA.

3. Results

In total, 274 patients (244 men, 30 women) participated in the study: 98 patients from New York and 176 patients from Los Angeles sites. Among the participants, 82 patients had detectable HIV antibodies, and 74 had antibodies for TP on reference tests. Among those positive for TP, 58 participants had reactive RPR (titer range = 1:1–1:512) with 15 with an RPR titer $\geq 1:8$. No rapid tests gave invalid results.

3.1. Performance of the INSTI Multiplex

Sensitivity for HIV antibodies was 98.8% (95% CI 93.4–99.9%), and specificity was 100% (95% CI, 98.1–100%). Sensitivity for TP antibodies was 56.8% (95% CI, 44.7–68.2%), and specificity was 98.5% (95% CI, 95.7–99.7%). Table 1 summarizes the performance of the INSTI Multiplex. Sensitivity among TP-reactive specimens varied based on the RPR titer, ranging from 25% (95% CI, 7.3–52.4%) in samples where RPR was nonreactive to 100% (95% CI, 78.2–100%) when the RPR titer was $\geq 1:8$ (Table 2). Among patients with HIV infection and RPR titer $\geq 1/8$ (8 patients), the agreement between the HIV rapid component and the reference laboratory assay was 100%. The agreement was also 100% between the TP component and the laboratory assay.

3.2. Performance of the INSTI HIV

The performance of the INSTI HIV was identical to the HIV component of the INSTI Multiplex (Table 1). Sensitivity for HIV antibodies was 98.8% (95% CI, 93.4–99.9%), and specificity was 100% (95% CI, 98.1–100%). There was only 1 false-negative result.

3.3. Performance of the Syphilis Health Check and comparison with the INSTI Multiplex

Sensitivity for TP-specific antibodies was 73% (95% CI: 61.4–82.6%), and specificity was 97% (95% CI, 93.6–98.9%) (Table 1). Among TPPA reactive specimens, sensitivity ranged from 43.8% (95% CI, 19.7–70.1%), when the RPR was nonreactive, to 100% (95% CI, 78.2–100%), when RPR titer was $\geq 1:8$ (Table 2). The Syphilis Health Check demonstrated

higher sensitivity than the INSTI Multiplex for treponemal antibody detection (73% versus 56.8%, $P = 0.04$).

4. Discussion

We conducted a field evaluation of the INSTI Multiplex, a dual rapid test for detection of HIV and syphilis, in clinical settings in the United States. The INSTI Multiplex showed excellent performance in detecting HIV antibodies. Unsurprisingly, the INSTI HIV showed identical performance to the HIV detection of the INSTI Multiplex as both test kits use the same antigens for detection of HIV antibodies. Performance of both tests was similar to the sensitivity and specificity reported by the manufacturer (bioLytical Laboratories Inc.), as well as previous studies evaluating the INSTI HIV on fingerstick whole blood samples (Adams et al., 2017; Bergman et al., 2013). This finding suggests that the addition of the TP component of the test does not negatively impact the detection of HIV antibodies.

The overall specificity for treponemal antibodies was very high (98.5%), but the sensitivity of the test is significantly lower (56.8%) than the one reported by the manufacturer (100%) (bioLytical Laboratories Inc.). Specimen type used for the evaluation, as well as the setting of the evaluation, may have affected the performance of the test (Gliddon et al., 2017). The manufacturer used contrived/spiked whole blood samples in the laboratory (bioLytical Laboratories Inc.), while in our study, we used fresh fingerstick whole blood specimens in a real-world clinical setting.

Another important finding is that the sensitivity of treponemal antibody detection increased with increasing RPR titers. This observation has also been reported on another dual HIV/syphilis test by Black et al. (2016). This finding is critical because those with higher RPR titers may be those with active or recent infection and therefore may be more likely to require treatment.

The performance of the INSTI Multiplex for both HIV and syphilis antibodies is similar to that of other dual devices. In a recent meta-analysis evaluating the performance of multiple dual tests, Gliddon et al. (2017) showed that the range of sensitivity in whole blood samples for HIV antibody detection was from 94% to 99% and the range of specificity was from 97% to 100%, while sensitivity for syphilis detection ranged between 47% and 96% and specificity ranged between 91% and 100%. In

Table 2

Sensitivity of the INSTI Multiplex and the Syphilis Health Check in TPPA-positive samples (n = 74) stratified by RPR titer.

RPR titer	INSTI Multiplex TP		Syphilis Health Check	
	Sensitivity (95% CI)	Samples detected	Sensitivity (95% CI)	Samples detected
Nonreactive	25% (7.3–52.4%)	4/16	43.8% (19.7–70.1%)	7/16
1/1 or 1/2	50% (7.3–52.4%)	17/34	73.5% (55.6–87.1%)	25/34
1/4	66.6% (29.9–92.5%)	6/9	77.8% (40–97.2%)	7/9
$\geq 1/8$	100% (78.2–100%)	15/15	100% (78.2–100%)	15/15

our study, we found that the performance of the INSTI Multiplex is within this range for both infections, indicating that the INSTI Multiplex performs as well as other dual rapid tests.

A recent performance evaluation of the Syphilis Health Check with fingerstick samples and TP-EIA as a reference standard showed similar performance to our results: sensitivity 71.4% (95% CI, 41.9–95.1%) and specificity 91.5% (95% CI, 87.5–95.5%) (Matthias et al., 2016). When compared to the syphilis component of the INSTI Multiplex rapid test, both tests showed high specificity. However, the FDA-cleared Syphilis Health Check demonstrated higher sensitivity than the INSTI Multiplex for treponemal antibody detection. The INSTI Multiplex utilizes 2 TP-specific antigens (tp17, tp47) (bioLytical Laboratories Inc.). In comparison, the FDA-approved Syphilis Health Check detects 3 TP-specific antigens (tp15, tp17, tp44) (Trinity Biotect Plc.), which could explain some of the difference in their performance.

Our study is subject to some limitations. The moderate sample size of the study limits the precision of our estimates, especially the small size of RPR titer subgroups. The test under evaluation (INSTI Multiplex) was not evaluated for acute HIV infections or cases of primary syphilis infection, so we cannot make estimates on its performance in those groups of patients. Additionally, our study did not perform further analyses to detect the HIV strains of participants with HIV infection. Based on the geographic distribution of HIV strains (Buonaguro et al., 2007), HIV-1 subtype B is the dominant genetic subtype in North America; thus, our study is likely to have evaluated the performance of the test kit on the particular strain. Further studies should be conducted to evaluate the performance in the various HIV strains and subtypes.

5. Conclusions

In conclusion, the INSTI Multiplex showed excellent performance in detecting HIV antibodies, while its sensitivity in detecting TP antibodies increased with increasing RPR titer. Furthermore, it is simple to use, with 1-min result turnover, and could be performed by nonmedical personnel. Considering the proven cost reduction dual rapid tests could yield and its performance, the test under evaluation could be used in high-prevalence areas or screening populations with history of syphilis or syphilis treatment. Further research is needed on how to best use those tests in clinical and outreach settings.

References

- Adams S, Luo W, Wesolowski L, Cohen SE, Peters PJ, Owen SM, et al. Performance evaluation of the point-of-care INSTI™ HIV-1/2 antibody test in early and established HIV infections. *J Clin Virol* 2017;91:90–4. [Internet]. [cited 2018 Mar 4]. Available from: <https://www.sciencedirect.com/science/article/pii/S1386653217300896?via%3Dihub>.
- Bergman J, Gratrix J, Plitt S, Fenton J, Archibald C, Wong T, et al. Feasibility and field performance of a simultaneous syphilis and HIV point-of-care test based screening strategy in at risk populations in Edmonton, Canada. *AIDS Res Treat* 2013;2013: 819593. [Internet]. [cited 2018 Mar 5]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24527210>.
- bioLytical Laboratories Inc. INSTI® Multiplex HIV-1/HIV-2/syphilis antibody test kit package insert. [Internet]. [cited 2018 Mar 10]. Available from: <http://biolytical.com/products/insti-multiplex/?country=CA>.
- Black V, Williams BG, Maseko V, Radebe F, Rees HV, Lewis DA. Field evaluation of Standard Diagnostics' Bioline HIV/Syphilis Duo test among female sex workers in Johannesburg, South Africa. *Sex Transm Infect* 2016;92(7):495–8.
- Bristow CC, Larson E, Anderson LJ, Klausner JD. Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. *Sex Transm Infect* 2016;92(5):340–6. [Internet]. [cited 2018 Feb 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26920867>.
- Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. *J Virol* 2007;81(19):10209–19. [Internet]. [cited 2018 Aug 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17634242>.
- Centers for Disease Control and Prevention. HIV Surveillance Report. 2016;vol. 28. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Accessed date: 10 March 2018. Published November 2017.
- Centers for Disease Control and Prevention. HIV in the United States | statistics overview. [Internet]. [cited 2018a Mar 10]. Available from: <https://www.cdc.gov/hiv/statistics/overview/ata glance.html>, 2018.
- Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. *Sex Transm Infect* 2017;93(S4): S3–15. [Internet]. [cited 2018 Feb 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28747410>.
- Herbst de Cortina S, Bristow CC, Vargas SK, Perez DG, Konda KA, Caceres CF, et al. Laboratory evaluation of a point-of-care downward-flow assay for simultaneous detection of antibodies to treponema pallidum and human immunodeficiency virus. *J Clin Microbiol* 2016;54(7):1922–4. [Internet]. [cited 2018 Feb 2]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27147725>.
- Matthias J, Dwiggins P, Totten Y, Blackmore C, Wilson C, Peterman TA. Evaluation of the Sensitivity and specificity of a commercially available rapid syphilis test — Escambia County, Florida, 2016. *MMWR Morb Mortal Wkly Rep* 2016;65(42):1174–5. [Internet]. [cited 2016 Nov 1]. Available from: <http://www.cdc.gov/mmwr/volumes/65/wr/mm6542a5.htm>.
- Trinity Biotect Plc. Syphilis health check. [Internet]. [cited 2017 Aug 22]. Available from: http://www.trinitybiotech.com/wp-content/uploads/2015/07/Syphilis-Health-Check-test_PL-rev-O-04-2015.pdf.
- Zetola NM, Klausner JD. Syphilis and HIV infection: an update. *Clin Infect Dis* 2007;44(9): 1222–8. [Internet]. [cited 2016 Sep 1]. Available from: <http://cid.oxfordjournals.org/lookup/doi/10.1086/513427>.